Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,732 across all filing types
Latest filing 2022-02-15 Director's Dealing
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
111年01月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, managers, and other key personnel. It includes data on shares held, increases, decreases, and trust shares, with specific references to identities and roles such as chairman, directors, general manager, and financial officers. The content is focused on insider share transactions and holdings rather than financial results, management commentary, or corporate governance policies. There is no indication of it being a full annual or quarterly report, earnings release, or any other financial report. The document is not a brief announcement or a proxy solicitation. It is a detailed insider shareholding disclosure, which aligns with the definition of Director's Dealing (DIRS) filings, which report personal share transactions by company directors and executives (insider trades). Therefore, the appropriate classification is DIRS.
2022-02-15 Chinese
111年01月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabular disclosure of shareholdings and pledged shares by insiders, including directors, supervisors, and senior management of the company 美時化學製藥股份有限公司. It lists share counts, pledged shares, and related party holdings. The content focuses on insider shareholdings and pledges rather than financial results, management changes, or meeting materials. This type of document corresponds to insider share transactions or holdings disclosures. According to the filing definitions, reports of personal share transactions or holdings by company directors and executives fall under Director's Dealing (DIRS). The document length is 3657 characters, which is consistent with a detailed insider shareholding report rather than a brief announcement or a full financial report. Therefore, the appropriate classification is DIRS with high confidence.
2022-02-15 Chinese
代重要子公司Alvogen Korea Holdings Ltd.公告召開2022年 股東常會
AGM Information Classification · 95% confidence The document is a formal announcement from a company (Alvogen Korea Holdings Ltd.) about the scheduling and agenda of its 2022 Annual General Meeting (AGM). It includes details such as the date and location of the AGM, items to be reported, discussed, and approved, including the 2021 business report, internal control report, auditor appointment, financial statements, and remuneration proposals. There is no actual financial data or detailed report content included, only the notice of the meeting and its agenda. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or announcements related to it. The document length is short (867 characters), and it is clearly an announcement of the AGM and its agenda rather than the full report or minutes. Therefore, the correct classification is AGM Information (AGM-R).
2022-02-15 Chinese
代重要子公司Alvogen Korea Co., Ltd.公告召開2022年 股東常會
AGM Information Classification · 95% confidence The document is a formal announcement from a company (Alvogen Korea Co., Ltd.) about the convening of its 2022 Annual General Meeting (AGM). It includes details such as the date of the board resolution, the date and location of the AGM, and the agenda items to be discussed at the meeting, including reports and financial statements for the year 2021. The document does not contain the actual reports or financial statements but rather announces the meeting and its agenda. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or announcements related to it. The document length is short and it is an announcement rather than the full report itself, so it is not classified as an Annual Report or other detailed financial report.
2022-02-15 Chinese
111年02月法人說明會簡報 — 179520220210E001.pdf
Investor Presentation Classification · 95% confidence The document is titled 'THIRD QUARTER 2021 RESULTS Investor Presentation' and contains detailed financial data for Q3 2021, including revenue, gross margin, operating expenses, net income, and EPS. It also includes business highlights, market leadership, regulatory updates, R&D pipeline, and capital structure information. The content is structured as a presentation with slides and charts, focusing on financial results, business strategy, and market position for the third quarter of 2021. This matches the definition of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. The document is not a full quarterly report (IR) because it is formatted as a presentation and includes forward-looking statements and strategic highlights rather than comprehensive financial statements. Therefore, the correct classification is Investor Presentation (IP).
2022-02-10 Chinese
111年02月法人說明會簡報 — 179520220210M001.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation of the company's Q3 2021 operational and financial results, including financial performance, product market share, R&D progress, and strategic initiatives. It contains substantive financial data such as revenue, gross profit, operating income, EPS, and market growth metrics. The document is titled as a Q3'21 operational results report and investor briefing, which aligns with a quarterly or interim report. It is not merely an announcement or a brief summary but a comprehensive report with financial statements and analysis for the quarter. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2021
2022-02-10 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.